Introduction
============

Choriocarcinoma is a highly malignant neoplasm that most commonly occurs in females and is related to a gestational event. In males, choriocarcinoma is generally considered a nonseminomatous germ cell tumor, which represents less than 5% of all germ cell tumors in males.[@b1-cmar-10-4565] Choriocarcinoma in males commonly develops in the gonads (ie, testes). In some cases, extragonadal choriocarcinoma occurs in midline locations, such as the mediastinum, retroperitoneum and pineal gland, with rare cases reported in the parenchymal organs, such as the lungs, gastrointestinal tract and breast.[@b2-cmar-10-4565]--[@b7-cmar-10-4565] Although the burden of extragonadal germ cell tumors has been previously described in population-based studies, extragonadal choriocarcinoma in males has not been specified.[@b8-cmar-10-4565],[@b9-cmar-10-4565]

Several hypotheses have been proposed by pathologists to explain the etiology of extragonadal choriocarcinoma: 1) the tumor arises from retained primordial germ cells that migrate abnormally during embryogenesis; 2) metastasis occurs from a gonadal choriocarcinoma that regressed spontaneously; and 3) development is a consequence of multidirectional tumor differentiation from a common stem cell in malignant epithelium. Recently, novel somatic and germline mutations have been reported to correlate with extragonadal germ cell tumors; however, strict pathological distinctions for the development of choriocarcinoma seem to be very difficult for pathologists to apply.[@b10-cmar-10-4565]--[@b12-cmar-10-4565] The etiology suggests that prognostic factors of extragonadal choriocarcinoma should not be implied from the extragonadal germ cell cancer or testicular choriocarcinoma, despite the 5-year relative survival rate of 71% and 68% for extragonadal germ cell cancer in Europe and in the USA, respectively, and the testicular choriocarcinoma 5-year survival rate of less than 80% in the USA.[@b9-cmar-10-4565],[@b13-cmar-10-4565],[@b14-cmar-10-4565] Based on previous case reports, the prognostic factors of extragonadal choriocarcinoma in males was not fully understood.

The Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute provides data on cancers in 18 geographical areas of the USA and covers \~26% of the population. We performed this population-based study to explore the incidence and prognostic factors of extragonadal choriocarcinoma in males and aimed to provide a more accurate estimate of the incidence and survival rate of this very rare disease.

Materials and methods
=====================

The SEER Program
----------------

Two cohorts of patients were created using the SEER program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database. One cohort to estimate the incidence was created using the SEER 9 Registries Research Data, November 2016 Submission (1973--2014)\<Katrina/Rita Population Adjustment\>. The other cohort to estimate the patient demographics and survival was created using SEER 18 Registries Research Data+Hurricane Katrina Impacted Louisiana Cases, November 2015 Submission (1973--2013 varying).

The selection of patients was based on 1) ICD for Oncology (ICD-O) codes of 9100/2: Choriocarcinoma in situ, NOS, 9100/3: Choriocarcinoma, NOS, 9101/2: Choriocarcinoma combined with other germ cell elements, in situ, 9101/3: Choriocarcinoma combined with other germ cell elements; 2) sex is male; 3) site is not "Testis -- male". Finally, one cohort of 115 eligible patients was enrolled to estimate the incidence and the other cohort of 197 eligible patients was enrolled to estimate the patient demographics and survival in this study.

Statistical analysis
--------------------

Incidence rates were analyzed with SEER\*Stat Software version 8.3.5 (Surveillance Research Program, National Cancer Institute, [seer.cancer.gov/seerstat](http://seer.cancer.gov/seerstat)). Trends in incidence rates were analyzed with the Joinpoint Regression Program (version 4.5.0.1; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute) using the Joinpoint regression model and permutation tests for identifying changes in trends.[@b15-cmar-10-4565] Statistical analysis was performed with SPSS Statistical Package version 24.0 (SPSS Inc, Chicago, IL, USA). Rates were per 100,000 and age was adjusted to the 2000 US standard population. Percent change was calculated using 1 year for each end point. The tumor stage was classified by SEER summary stage 1977 (1995--2000). Marital status was divided into two groups: married and others, which included never married, widowed, divorced, separated, unmarried or domestic partner, and unknown. The age at diagnosis between two groups was compared using a *t*-test. Rates of surgery and beam radiation treatment between groups were compared using chi-squared test. The 1-, 3- and 5-year cause-specific survival (CSS) rates were estimated by the life table method, and median survival rates were estimated by Kaplan--Meier analyses and then compared statistically using the log-rank test. The prognostic factors were determined by univariate regression analysis, where HRs with 95% CIs were calculated to estimate the risk of death. A multivariable analysis was further performed to find independent prognostic factors using the Cox proportional hazards. *P*\<0.05 was considered statistically significant.

Ethical approval
----------------

The ethical approval and informed consent statements are not applicable for this type of research. The data accessed from the SEER database are freely available.

Results
=======

Incidence
---------

Between 1973 and 2014, a total of 115 male patients exhibiting extragonadal choriocarcinoma were identified in the SEER nine registries. The overall incidence rate for extragonadal choriocarcinoma in males during that period based on the SEER data was 0.022 per 100,000 people (95% CI: 0.018 to 0.026). In 1977 and 2014, the frequency was zero, which cannot be processed by Joinpoint trend analysis; therefore, we calculated the age-adjusted rates from 1978 to 2013 instead. The incidence of extragonadal choriocarcinoma in males changed from 0.0072 per 100,000 people in 1978 to 0.0430 in 1981, with an annual percent change (APC) of 23.23 and then dropped to 0.0272 in 2013 with an APC of --3.09 (95% CI=--4.9 to --1.3, *P*\<0.05), demonstrating no significant change from 1981 to 2013 ([Figure 1](#f1-cmar-10-4565){ref-type="fig"}).

Patient demographics
--------------------

From 1973 to 2013, 197 cases of extragonadal choriocarcinoma in males were identified in the SEER database. Patient demographics and clinical characteristics of the study population are summarized in [Table 1](#t1-cmar-10-4565){ref-type="table"}. The median age of diagnosis was 30 years with a range of 0--84 years and percentile of 21--46 years. The most common primary tumor location was the mediastinum, with 44.8% of cases occurring in this location (n=30), followed by the retroperitoneum and the brain. Other tumor sites included the liver (n=2), intrahepatic bile duct (n=1), nasal cavity (n=1), subcutaneous connective tissue (n=2), adrenal gland (n=1) and abdomen (n=1).

Treatment
---------

The ratio of patients who received beam radiation therapy was 22.8% for the whole cohort but was lower in older patients and European-Americans, and the ratio receiving surgery was 63.5% overall, which has decreased over the last decades. Among the tumors located at different sites, brain tumor patients were more prone to receive beam radiation, and mediastinum tumor patients were less likely to receive surgery. The treatment characteristics of the cohort are shown in [Table 2](#t2-cmar-10-4565){ref-type="table"}.

Survival
--------

The median follow-up time was 9 months (with a range of 0--427 months). The median survival time of the cohort was 11 months (95% CI: 5.7 to 16.3 months), whereas the estimated 1-, 3- and 5-year overall survival rates were 46%, 33% and 31%, respectively. The estimated 1-, 3- and 5-year CSS rates were 49%, 37% and 35%, respectively.

The multivariate analysis showed that the age at diagnosis and primary site were the independent prognostic factors ([Table 3](#t3-cmar-10-4565){ref-type="table"}). First, age at diagnosis was related to prognosis in the univariate CSS analysis. Compared with older patients, younger patients were significantly correlated with a favorable prognosis of survival. The median survival time ([Figure 2](#f2-cmar-10-4565){ref-type="fig"}) was 186 months for the 0- to 19-year-old patients; 13 months in the 20- to 49-year-old patients; and only 4 months in patients aged 50+ years. The multivariate analysis showed that age at diagnosis was an independent prognostic factor. In addition, the brain as the primary site was related to a favorable prognosis in both univariate and multivariate analyses. The median survival time was 193 months for brain tumors and 12 months for mediastinum tumors.

The variables of diagnosis year and marital status were related to prognosis in our univariate analysis but were not identified as independent prognostic factors in our multivariate analysis. For year of diagnosis, the survival rate tended to increase along decades, and the median survival times were 5, 10, 13 and 20 months in 1973--1982, 1983--1992, 1993--2002 and 2003--2013, respectively. For marital status, we found married patients were related to an unfavorable prognosis in the univariate analysis, but the multivariate analysis excluded it as an independent prognostic factor. To elucidate the reason, we compared the age at diagnosis in married patients with the other marital categories using the *t*-test. The results showed a significantly younger age at diagnosis in married patients than the other marital categories (28.0±16.5 years vs 44.9±15.0 years, *P*=0.000).

Other variables, such as ethnicity and therapeutic treatment (ie, surgery vs beam radiation), were not prognostic factors in the multivariate analysis. First, ethnicity was not correlated to prognosis, despite a worse prognosis for African-American patients when compared with European-American patients or others. Second, surgery and beam radiation treatments were not correlated to prognosis. In fact, the number of surgeries dropped from 77.4% in 1973--1999 to 51.0% in 2000--2013, *P*=0.000. However, the percentage of beam radiation cases was similar at 19.4% and 26.0% in the previous and current centuries, respectively (*P*=0.270).

Discussion
==========

In the present study, we took advantage of the large data set from the SEER Program to investigate the incidence and prognostic factors in the largest series of extragonadal choriocarcinoma in males reported to date. The retrospective study showed that the rates of beam radiation and surgery cases were 22.8% and 63.5%, respectively, and the 5-year CSS rate was 35%. The age at diagnosis and primary site were the independent prognostic factors.

Despite the multiple hypotheses of tumor development, choriocarcinoma is a rare neoplasm, and to the best of our knowledge, the incidence of extragonadal choriocarcinoma in males was first reported in a population-based cohort. Most importantly, according to data collected by Jiang et al,[@b16-cmar-10-4565],[@b17-cmar-10-4565] gestational choriocarcinoma affected 1--9.2 in 40,000 pregnancies and 1 in 40 hydatidiform moles, and the inci dence ratio of gestational choriocarcinoma to nongestational choriocarcinoma was 79:1, with a male-to-female ratio of 13:33 among patients with nongestational choriocarcinoma. Moreover, nongestational choriocarcinoma in males has been reported at variable anatomical sites with the most occurring in the testes. A total of 106 cases of male choriocarcinoma were reviewed between 1995 and 2006 by Yokoi et al, and the testes were the most common primary tumor site accounting for 33% (35/106).[@b18-cmar-10-4565] However, testicular choriocarcinoma represents only less than 1% of all germ cell tumors.[@b2-cmar-10-4565],[@b19-cmar-10-4565] Interestingly, extragonadal germ cell tumors occur more frequently in the Korean population than in western countries, and the authors considered genetic and dietary factors as possible explanations for the difference.[@b20-cmar-10-4565] The extragonadal germ cell tumor rate among males in the USA is 1.82 times higher than that in Europe, and the authors think that miscoding of registries could be a likely explanation.[@b8-cmar-10-4565],[@b9-cmar-10-4565] However, choriocarcinoma was not specified in these studies and was merely described in case reports. For example, the primary mediastinal choriocarcinoma was first described by Arendt in 1931, and only 43 subsequent reports were found by 2014.[@b3-cmar-10-4565] Zhu et al's literature review of primary pulmonary choriocarcinoma in males reflected only 29 cases reported by 2016.[@b5-cmar-10-4565] In our study, the incidence of extragonadal choriocarcinoma in males estimated by SEER data was 0.022/100,000 people, and the incidence decreased from 1981.

Extragonadal choriocarcinoma occurs more frequently in younger male patients rather than in older male patients, and furthermore, younger age is a prognostic factor. On the one hand, although there are potentially different mechanisms of development between testicular and extragonadal choriocarcinoma, we found a similar age in peak incidence between the two. The highest incidence of testicular cancer in the USA is between 20 and 34 years old, and the majority of new testicular choriocarcinoma cases develop between 25 and 30 years of age.[@b14-cmar-10-4565] In our study, the peak incidence of extragonadal choriocarcinoma in males was 20--29 years old, and the majority was younger than 50 years. These findings are in agreement with a literature review involving 41 cases of primary mediastinal choriocarcinoma, which is usually diagnosed in young patients aged between 20 and 30 years old.[@b3-cmar-10-4565] However, 26 cases of primary choriocarcinoma of the bladder and 53 cases of primary gastric choriocarcinoma reported in the literature showed that the majority of patients were diagnosed at 50+ years of age, and Serno et al found that the median age of male primary pulmonary choriocarcinoma was 60 years.[@b6-cmar-10-4565],[@b21-cmar-10-4565],[@b22-cmar-10-4565] Therefore, we speculate that choriocarcinoma at midline locations mainly occurs in young patients, while choriocarcinoma of parenchymal organs tends to affect older patients. On the other hand, our data show that patients who are younger than 20 years have a favorable prognosis. Similarly, Jiang et al analyzed 13 cases of male primary choriocarcinoma reported from the medical center and 100 cases from the scientific literature, and discovered that patients not older than 34 years had significantly longer survival rates.[@b17-cmar-10-4565] In fact, the International Federation of Gynecology and Obstetrics 2000 prognostic scoring system was widely used to estimate the prognosis for gestational trophoblastic neoplasia, and age is a prognostic factor.[@b23-cmar-10-4565] A recent study found that age, ethnicity and tumor stage were independent predictors of mortality of gestational choriocarcinoma.[@b24-cmar-10-4565] Therefore, the findings imply that age is a critical prognostic factor for choriocarcinoma.

Taken together, the tumorigenesis and prognosis of younger patients seem different from those of older patients, and these findings indicate that more detailed research should be undertaken in the context of pathology and molecular genetics.

In our study, the most common sites of extragonadal choriocarcinoma in males were the mediastinum, retroperitoneum and brain, among which the brain is the primary site directly correlated to a favorable prognosis. Interestingly, the incidence in anatomical locations of extragonadal choriocarcinoma was slightly different from the case series. Yokoi et al described the largest series of 106 cases of male choriocarcinoma reported during 1995--2006, and in addition to testes, the mediastinum, pineal body, gastrointestinal tract, lungs and retroperitoneum were the most common sites; similar results were described by Jiang et al in 2014.[@b17-cmar-10-4565],[@b18-cmar-10-4565] Publication bias was inevitable because a literature review of previously published case reports formed the majority of data in both studies. However, the present population-based study provides an overall view of the extragonadal choriocarcinoma in males. Additionally, although choriocarcinoma of the brain was correlated to a favorable prognosis compared with that of the mediastinum, it could be fatal in more than half the patients. A previous study that included intracranial choriocarcinoma in men and women found that the 1-year survival rate was 61.2%, and the prognosis of male patients was better than that of females.[@b25-cmar-10-4565] Choriocarcinoma is the rarest and most malignant of primary intracranial germ cell tumors, accounting for \~3%--5% of all intracranial GCTs, and germ cell tumors comprised 3%--11% of all intracranial neoplasms in children and 1% of all primary intracranial neoplasms in adults.[@b26-cmar-10-4565],[@b27-cmar-10-4565] The most common sites of intracranial choriocarcinoma are the pineal and suprasellar regions. Characteristic clinical features include tumor hemorrhage, extraneural and cerebrospinal fluid metastasis, and fetal problems of intracranial choriocarcinoma; these features contribute to its poor prognosis.[@b25-cmar-10-4565]

The treatment for primary choriocarcinoma has remained unclear without any standard strategies, and no clinical trial has been reported because of the rarity of this disease; therefore, clinicians often provide patients with surgery, chemotherapy and radiotherapy as choices for treatment.[@b28-cmar-10-4565] Surprisingly, our study did not find that beam radiation or surgery could prolong survival, and further analysis showed that neither radiotherapy nor surgery could prolong survival in a subgroup of intracranial tumors. However, a previous literature review based on 66 reported cases in 1975--2004 revealed that surgery, radiotherapy and chemotherapy were independent prognostic factors in primary intracranial choriocarcinoma/germ-cell tumors with high levels of human chorionic gonadotropin (HCG), although the case selection bias and different treat ment protocols should not be overlooked.[@b25-cmar-10-4565] We believe that the treatment efficacy can be omitted in our study because of the limited number of cases. Therefore, we conclude that the best management is based on multidisciplinary therapy, and multicenter clinical trials should be encouraged.

The limitations of this current study include the following: 1) the lack of central verification of pathology diagnosis; 2) the unavailability of information of treatment such as chemotherapy and surgical margin in the SEER database, which may be a critical prognostic factor; 3) the lack of information of biomarkers, such as HCG; 4) and the relatively small sample size, which may still not be enough to fully illustrate the incidence, treatment and prognosis of this rare tumor.

Conclusion
==========

The present study suggests that extragonadal choriocarcinoma in males is a rare malignancy with a poor prognosis. However, a young age at diagnosis and the brain as the primary tumor site were the independent prognostic factors.

This work was not supported by any organization. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

**Author contributions**

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

![The incidence of extragonadal choriocarcinoma in male from 1978 to 2013.\
**Notes:** Annual age-adjusted rates of extragonadal choriocarcinoma in male by year (1973--2013). The incidence is presented as the number of patients per 100,000 age-adjusted for the 2000 US standard population.](cmar-10-4565Fig1){#f1-cmar-10-4565}

![Plots of cause-specific survival (CSS) duration.\
**Notes:** (**A**) CSS for the cohort of extragonadal choriocarcinoma in male. (**B**) CSS by age of diagnosis. Patients were separated into three groups by age of diagnosis. Five-year CSS was 57%, 33% and 15% for those diagnosed among 0--19 years, 20--49 years and 50+ years (*P*\<0.05), respectively. (**C**) CSS by primary site. Selected patients were separated into three groups by the primary site of tumor. Five-year CSS was 25%, 54%, and 71% for patients of mediastinum, retroperitoneum, and brain tumors.](cmar-10-4565Fig2){#f2-cmar-10-4565}

###### 

Demographics and clinical characteristics

  Characteristic                                            N     Percentage
  --------------------------------------------------------- ----- ------------
                                                                  
  Sample size                                               197   100.0%
  Age groups, years                                               
   0-9                                                      6     3.0%
   10-19                                                    34    17.3%
   20-29                                                    55    27.9%
   30-39                                                    36    18.3%
   40-49                                                    25    12.7%
   50-59                                                    16    8.1%
   60-69                                                    18    9.1%
   70-79                                                    5     2.5%
   80+                                                      2     1.0%
  Year of diagnosis                                               
   1973-1982                                                26    13.2%
   1983-1992                                                35    17.8%
   1993-2002                                                54    27.4%
   2003-2013                                                82    41.6%
  Race                                                            
   White                                                    158   80.2%
   Black/African American                                   17    8.6%
   Other                                                    22    11.2%
   Marital status                                                 0.0%
   Married                                                  79    40.1%
   Others                                                   118   59.9%
  Grade                                                           
   Well differentiated                                      0     0.0%
   Moderately differentiated                                1     0.5%
   Poorly differentiated                                    18    9.1%
   Undifferentiated                                         8     4.1%
   Unknown                                                  170   86.3%
  Location                                                        
   Mediastinum                                              67    34.0%
   Retroperitoneum                                          27    13.7%
   Brain (nonpineal)                                        11    5.6%
   Brain (pineal)                                           7     3.6%
   Gastrointestinal                                         10    5.1%
   Bronchus/Lung                                            6     3.0%
   Other                                                    8     4.1%
   Unknown                                                  61    31.0%
  Histopathology                                                  
   Choriocarcinoma, NOS                                     154   78.2%
   Choriocarcinoma combined with other germ cell elements   43    21.8%
  Stage                                                           
   Localized                                                4     2.0%
   Regional                                                 3     1.5%
   Distant                                                  13    6.6%
   Unknown                                                  177   89.8%

###### 

Treatment characteristics of choriocarcinoma out of testicle in males

  Characteristic                                                  Beam radiation   Surgery                             
  --------------------------------------------------------- ----- ---------------- --------- ------- -------- -------- -------
                                                                                                                       
  Overall                                                   197   22.8%                              63.5%             
  Age groups, years                                                                6.211     0.045            2.377    0.305
   0-19                                                     40    32.5%                              57.5%             
   20-49                                                    116   24.1%                              62.1%             
   50+                                                      41    9.8%                               73.2%             
  Year of diagnosis                                                                1.108     0.775            35.243   0.000
   1973-1982                                                26    15.4%                              100.0%            
   1983-1992                                                35    25.7%                              88.6%             
   1993-2002                                                54    22.2%                              48.1%             
   2003-2013                                                82    24.4%                              51.2%             
  Race                                                                             6.902     0.032            0.173    0.917
   White                                                    158   19.0%                              63.9%             
   Black/African American                                   17    35.3%                              58.8%             
   Other                                                    22    40.9%                              63.6%             
  Marital status                                                                   3.053     0.081            0.752    0.386
   Married                                                  79    16.5%                              67.1%             
   Others                                                   118   27.1%                              61.0%             
  Primary site                                                                     29.075    0.000            28.269   0.000
   Mediastinum                                              67    13.4%                              44.8%             
   Retroperitoneum                                          27    18.5%                              51.9%             
   Brain                                                    18    72.2%                              66.7%             
   Other                                                    24    16.7%                              62.5%             
   Unknown                                                  61    23.0%                              88.5%             
  Histopathology                                                                                                       
   Choriocarcinoma, NOS                                     154   20.8%            1.704     0.192   64.3%    0.212    0.646
   Choriocarcinoma combined with other germ cell elements   43    30.2%                              60.5%             

###### 

Univariate and multivariate survival analyses for evaluating the prognostic factor of choriocarcinoma out of testis in males

  Variable                                                  N      Log-rank   Univariate analysis   Multivariate analysis                                                                                                 
  --------------------------------------------------------- ------ ---------- --------------------- ----------------------- ---------------------- ----------- ------------------------- ------- ------------------------ -------
                                                                                                                                                                                                                          
  Age groups, years                                                                                                                                0.000                                                                  
   0-19                                                     40     66%        60%                   57%                     186 (13.7 to 358.3)    Reference   1.000                             1.000                    0.019
   20-49                                                    1 16   49%        34%                   33%                     13 (5.85 to 20.15)     0.030       0.31 1 (0.172 to 0.561)   0.000   0.384 (0.186 to 0.790)   0.009
   50+                                                      41     32%        21%                   15%                     4 (0.00 to 9.55)       0.000       0.537 (0.350 to 0.824)    0.004   0.558 (0.345 to 0.901)   0.017
  Year of diagnosis                                                                                                                                0.129                                                                  
   1973-1982                                                26     34%        21%                   21%                     5 (0.0 to 10.0)        Reference   1.000                             1.000                    0.278
   1983-1992                                                35     46%        34%                   34%                     10 (0.0 to 21.1)       0.144       1.819 (1.083 to 3.054)    0.024   1.706 (0.996 to 2.923)   0.052
   1993-2002                                                54     49%        37%                   35%                     13 (4.9 to 21.1)       0.086       1.206 (0.727 to 2.001)    0.468   1.152 (0.691 to 1.922)   0.587
   2003-2013                                                82     56%        44%                   39%                     20 (7.4 to 18.6)       0.036       1.154 (0.735 to 1.813)    0.533   1.132 (0.716 to 1.788)   0.596
  Race                                                                                                                                             0.803                                                                  
   White                                                    158    50%        37%                   35%                     13 (6.18 to 19.8)      Reference   1.000                                                      
   Black/African American                                   17     38%        31%                   21%                     8 (5.1 to 10.9)        0.538       0.950 (0.542 to 1.664)    0.856                            
   Other                                                    22     51%        39%                   39%                     15 (0.0 to 31.5)       0.835       1.152 (0.533 to 2.492)    0.719                            
  Marital status                                                                                                                                   0.034                                                                  
   Married                                                  79     39%        27%                   27%                     9 (6.0 to 12.0)        Reference   1.000                             1.000                    0.514
   Others                                                   1 18   56%        43%                   40%                     20 (7.4 to 32.6)       0.034       1.449 (1.015 to 2.067)    0.041   1.142 (0.767 to 1.700)   
  Primary site                                                                                                                                     0.008                                                                  
   Mediastinum                                              67     49%        27%                   25%                     12 (5.8 to 18.2)       Reference   1.000                             1.000                    0.176
   Retroperitoneum                                          27     58%        54%                   54%                     NA                     0.074       0.763 (0.506 to 1.150)    0.196   0.925 (0.599 to 1.428)   0.724
   Brain                                                    18     82%        82%                   73%                     193 (178.6 to 207.4)   0.01 1      0.422 (0.222 to 0.802)    0.008   0.483 (0.250 to 0.933)   0.030
   Other                                                    24     44%        44%                   44%                     5 (0.9 to 9.1)         0.452       0.312 (0.133 to 0.734)    0.008   0.564 (0.215 to 1.479)   0.244
   Unknown                                                  61     39%        27%                   25%                     8 (3.9 to 12.1)        0.175       0.870 (0.468 to 1.618)    0.659   0.721 (0.376 to 1.383)   0.325
  Histopathology                                                                                                                                   0.228                                                                  
   Choriocarcinoma, NOS                                     154    46%        35%                   33%                     12 (5.5 to 18.5)       Reference   1.000                                                      
   Choriocarcinoma combined with other germ cell elements   43     60%        42%                   42%                     20 (0.0 to 43.7)       0.228       1.290 (0.841 to 1.979)    0.243                            
  Beam Radiation                                                                                                                                   0.745                                                                  
   Yes                                                      45     48%        39%                   35%                     13 (3.8 to 22.2)       Reference   1.000                                                      
   No                                                       152    49%        36%                   34%                     13 (6.7 to 19.3)       0.745       1.068 (0.708 to 1.613)    0.753                            
  Surgery                                                                                                                                          0.954                                                                  
   Yes                                                      125    51%        37%                   35%                     16 (7.6 to 24.4)       Reference   1.000                                                      
   No                                                       72     46%        36%                   34%                     12 (7.3 to 16.7)       0.954       1.01 1 (0.699 to 1.462)   0.956                            

**Abbreviations:** CSS, cause-specific survival; N/A, not applicable.
